Respecta® (MD)

The ultimate oral solution to promote healthy vaginal microbiota.

Product background

The microbial species that inhabit the vaginal tract play an important role in the maintenance of health, and prevention of infection. Specific Lactobacillus strains were found effective in the protection of the genital tract against pathogens responsible of bacterial vaginosis (BV), vulvovaginal candidiasis (VVC) and aerobic vaginitis (AV). Respecta® is a unique medical device (class IIA) with a proven mechanism of action clinically tested in women to restore and maintain a healthy vaginal flora.

Key ingredients

Respecta® complex.

Target

Women under antimicrobic treatment for BV and VVC; asymptomatic women with BV; women with abnormal vaginal flora and aerobic vaginitis; women undergoing long-term antibiotic treatment because recurrent UTI; women with unhealthy microflora at higher risk of developing UTI.

Benefits and features

  • Unique proprietary formula
  • Proven to colonize the vaginal tract
  • Restores vaginal microbiota either alone or in combination with drugs
  • Improves symptoms and signs of BV and VVC
  • Helps to reduce episodes of BV and VVC
  • Adjuvant to conventional antimicrobic treatments
  • Non-invasive safe solution
  • Approved medical device class IIA in EU

Scientific evidence and proprietary studies

Lactobacilli vaginal colonization after oral consumption of Respecta complex: a randomized controlled pilot study. (De Alberti et al 2015) – Effects of L. rhamnosus and L. acidophilus on bacterial vaginal pathogens. (Bertuccini et al 2017) – Lactobacilli and lactoferrin: biotherapeutic effects for vaginal health. (Bertuccini et al 2018) – L. rhamnosus ATCC SD5675 and L. acidophilus LMG S29159 attenuate G. vaginalis-infected bacterial vaginosis in mice (Jang et al 2017) – Study on the effects of an oral lactobacilli and lactoferrin complex in women with intermediate vaginal microbiota. (Russo et al 2018) – Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomised clinical trial. (Russo et al 2019) – Randomised clinical trial in women with Recurrent Vulvovaginal Candidiasis: Efficacy of probiotics and lactoferrin as maintenance treatment. (Russo et al 2019).

Product name Respecta®
Status Medical Device class IIA
Key ingredients Respecta® complex
Target and indication Restores vaginal microbiota BV e VVC
Claims EFSA n. a.
Scientific evidence and proprietary study Lactobacilli vaginal colonization after oral consumption of Respecta complex: a randomized controlled pilot study. (De Alberti et al 2015) - Effects of L. rhamnosus and L. acidophilus on bacterial vaginal pathogens. (Bertuccini et al 2017) - Lactobacilli and lactoferrin: biotherapeutic effects for vaginal health. (Bertuccini et al 2018) - L. rhamnosus ATCC SD5675 and L. acidophilus LMG S29159 attenuate G. vaginalis-infected bacterial vaginosis in mice (Jang et al 2017) - Study on the effects of an oral lactobacilli and lactoferrin complex in women with intermediate vaginal microbiota. (Russo et al 2018) - Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomised clinical trial. (Russo et al 2019) - Randomised clinical trial in women with Recurrent Vulvovaginal Candidiasis: Efficacy of probiotics and lactoferrin as maintenance treatment. (Russo et al 2019).
Pharmaceutical form Oral capsules (10 or 20veggie capsules in alu/alu blister)

Are you interested in this product?

We respond to any technical or commercial request: